News | February 03, 2014

Pulmonary Embolism Trial Compares Endovascular Ultrasound to Anticoagulation

Ekos BTG EkoSonic Endovascular System Pulmonary Embolism PE Thrombectomy
February 3, 2013 — Ekos Corp., a BTG International group company, published results of its Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (PE) trial (ULTIMA) in the peer-reviewed journal of the American Heart Association, Circulation. The announcement was made at the International Symposium on Endovascular Therapy (ISET), Miami, Fla.
 
The ULTIMA study is a prospective randomized controlled clinical trial of patients with submassive PE treated with either intravenous anticoagulation or the Ekos EkoSonic Endovascular System and rt-PA. Ekos’ technology uses ultrasound to accelerate the action of clot-dissolving drugs. Dr. Nils Kucher, director of the Venous Thromboembolism Research Group at the University Hospital in Bern, Switzerland, is lead author and principal investigator of the ULTIMA study.
 
Patients treated with the Ekos EkoSonic Endovascular System demonstrated a statistically significant reduction in right heart strain within 24 hours with no adverse effects from the catheterization. Patients treated only with the anticoagulant heparin showed no significant improvement. In the Ekos group, the mean RV/LV ratio was reduced from 1.28±0.19 at baseline to 0.99±0.17 at 24 hours (p<0.001); in the heparin group, mean RV/LV ratio was 1.20±0.14 and 1.17±0.20, respectively (p=0.31). The mean decrease in RV/LV ratio from baseline to 24 hours was 0.30±0.20 versus 0.03±0.16 (p<0.001), respectively. There were no serious bleeding events in either group. There was one death in the non-Ekos group within 90 days for reasons other than PE.
 
For PE patients at intermediate risk of bad outcomes, the ULTIMA trial demonstrated that Ekos treatment was clinically superior to anticoagulation with heparin alone in reversing right ventricular dilation at 24 hours, without an increase in bleeding complications.
 
For more information: ekoscorp.com

Related Content

ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Technology | Pulmonary Embolism| March 01, 2017
March 1, 2017 — BTG plc announced U.S.
global thrombectomy devices market, Allied Market Research report, 2022
News | Thrombectomy Devices| January 05, 2017
January 5, 2017 — A new report published by Allied Market Research forecasts that the global...
News | Analytics Software| October 31, 2016
In an effort to improve patient care, Children's Hospital of Philadelphia's (CHOP) Information Services team is using...
Neuravi, EmboTrap II stent retriever, thrombectomy device, acute stroke, European launch, CE Mark
News | Thrombectomy Devices| September 28, 2016
Neuravi recently announced Conformité Européenne (CE) Mark approval and launch of the company’s newly available...
ICU use for heart failure
News | Heart Failure| August 09, 2016
August 9, 2016 – With the use of intensive care units (ICUs) on the rise in many hospitals, researchers at LA BioMed
Penumbra System, ACE68 Reperfusion Catheter, thrombectomy device, SNIS 2016, acute ischemic stroke patients
Technology | Thrombectomy Devices| July 27, 2016
July 27, 2016 — Penumbra Inc. announced U.S.
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
Overlay Init